en.Wedoany.com Reported - Mayo Clinic, in collaboration with the Princess Margaret Cancer Centre in Toronto, published a study in *Nature Genetics* that maps the most detailed meningioma atlas to date, revealing how the tumor microenvironment influences disease behavior and patient prognosis. Meningioma is the most common brain tumor in adults, with approximately 30,000 to 40,000 cases diagnosed annually in the United States. The study analyzed hundreds of tumor samples, utilizing single-cell sequencing and spatial transcriptomics to create a high-resolution atlas of over 500,000 individual cells and millions of data points, showing the genetic footprint of individual cells, spatial variations within the tumor, and cell-to-cell interactions.
Researchers identified multiple distinct immune cell states, with a particular focus on the behavioral differences of myeloid cells across various tumors. Some of these cell states were associated with more aggressive disease, while others correlated with better prognosis. Traditional meningioma grading systems fail to fully capture the complex behavior of tumors, and this finding drives the development of molecular classification tools to more accurately predict the risk of postoperative tumor recurrence.
The study indicates that certain immune cell programs are closely linked to the speed of tumor recurrence. These signals can complement existing grading and molecular classification systems, aiding in optimizing decisions regarding surgery, radiotherapy, or surveillance. Additionally, these biological features may be detectable through non-invasive methods, such as blood biomarkers, offering the potential for long-term monitoring without surgery. The research also identified communication pathways between immune cells and tumor cells, providing direction for developing new targets to slow tumor growth or enhance treatment response.
Next steps include validating these findings in larger, multicenter cohorts and translating biological insights into clinical tools and prospective trials. The study was led by senior author Dr. Gelareh Zadeh, M.D., Ph.D., a neurosurgeon at Mayo Clinic.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
